[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604280":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":13,"responsibleParty":54,"collaborators":56,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":7,"maxAge":7,"enrollmentInfo":75,"targetDuration":7,"studyType":78,"phases":7,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Isabelle DURAND-ZALESKI, Professor","Greater Paris University Hospitals","PRINCIPAL_INVESTIGATOR",[14,33,43],{"facility":15,"status":16,"city":17,"state":7,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Centre Leon Berard","RECRUITING","Lyon","69000","France","FR",{"type":22,"coordinates":23},"Point",[24,25],4.84789,45.74906,{"lat":25,"lon":24},[28],{"name":29,"role":30,"phone":31,"phoneExt":7,"email":32},"PIERRE DR SAINTIGNY, DR","CONTACT","04 78 78 28 67","Pierre.SAINTIGNY@lyon.unicancer.fr",{"facility":34,"status":35,"city":36,"state":7,"zip":37,"country":19,"countryCode":20,"cosmosGeoPoint":38,"geoPoint":42,"contacts":7},"APHP Hôtel Dieu URC Economie de la sante \u002FURC ECO","ACTIVE_NOT_RECRUITING","Paris","75004",{"type":22,"coordinates":39},[40,41],2.3488,48.85341,{"lat":41,"lon":40},{"facility":44,"status":16,"city":36,"state":7,"zip":45,"country":19,"countryCode":20,"cosmosGeoPoint":46,"geoPoint":48,"contacts":49},"HOPITAL AP-HP Cochin","75005",{"type":22,"coordinates":47},[40,41],{"lat":41,"lon":40},[50],{"name":51,"role":30,"phone":52,"phoneExt":7,"email":53},"Camille Pr TLEMSANI, PUPH","01 58 41 14 54","camille.tlemsani@aphp.fr",{"type":55,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[57,60,61,64],{"name":58,"class":59},"AuraGen Aesthetics LLC","INDUSTRY",{"name":15,"class":6},{"name":62,"class":63},"Laboratoire SeqOIA","UNKNOWN",{"name":65,"class":63},"PLAN FRANCE MÉDECINE GÉNOMIQUE 2025","100604280","performance-indicators-and-impact-on-the-care-pathway-of-sequencing-on-the-seqoia-and-auragen-seqogen-platforms-for-oncology-patients-100604280",false,"NCT07147465","Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients","Indicateurs de Performance et Impact Sur le Parcours de Soins du Séquençage Sur Les Plateformes Seqoia et Auragen (Seqogen) Pour Les Patients en Oncologie","SONCO","Inclusion Criteria:\n\n* Patients diagnosed with cancer and referred for high-throughput sequencing\n* Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.\n\nConsent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use.\n\nExclusion Criteria:\n\n* Opposition to data reuse, unvalidated upstream RCP","ALL",{"count":76,"type":77},3149,"ESTIMATED","OBSERVATIONAL","As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.\n\nThe SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records.\n\nThis cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.",[81,82,83,84],"Cancer","NGS","Tumor","RARE DISEASE",[86,87,88,89,90],"Oncology","genomic medecine","cancer","rare diseases","next-generation sequencing","2025-08-22",{"date":93,"type":94},"2025-08-29","ACTUAL",{"date":96,"type":94},"2025-07-01",{"date":98,"type":77},"2026-09-30",{"name":5,"class":6},3]